← Leaderboards
Michael J Barry
Massachusetts General Hospital
$2,469,243
Attributed
$6,638,060
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,638,060 · 4
AHRQ$0 · 1
By mechanism
U01$5,795,791 · 1
R34$457,435 · 1
R21$359,072 · 1
R01$25,762 · 2
Top collaborators
- Hyon K Choi5 shared
- Daniel Hal Solomon5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jennifer Temel$9,010,566
- Nancy A Rigotti$18,154,837
- Andrew T Chan$39,910,857
- Jonathan P Winickoff$16,869,989
- Benjamin P Linas$16,281,715
Others in their field
Top investigators on “Caring”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$279,179,778
- Chanza Baytop · Westat, Inc.$271,217,917
- Larry Arthur$256,720,406
Research focus
CaringInflammatory ArthritisArthropathiesDiabetes MellitusGuidelinesEvidence BaseCardiologyChronic Kidney FailureConsensusCrystal FormationAffectFlareAccident And Emergency DepartmentArthritisFundingAcuteCardiovascular SystemChronicAmericanClinical TrialsBone ErosionAmerican College Of PhysiciansGoutJoint Injury
Grant awards (12)
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$1,812,686
U01 · FY2025 · AR
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$1,937,050
U01 · FY2024 · AR
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$2,046,055
U01 · FY2023 · AR
Planning for a Trial of Comparative Effectiveness of Gout Management Strategies$217,868
R34 · FY2021 · AR
Planning for a Trial of Comparative Effectiveness of Gout Management Strategies$239,567
R34 · FY2020 · AR
Breast Cancer Screening and Follow-up in a PBRN: The Ma*$165,333
R21 · FY2007 · CA · contact PI
Breast Cancer Screening and Follow-up in a PBRN: The Ma*$193,739
R21 · FY2006 · CA · contact PI
ASSESSING TREATMENT RELATED HARMS IN PROSTATE CANCER, MASS. GEN. H. CONSORTIUM$25,762
R01 · FY2005 · CA
PROSTATE CANCER SCREENING &MORTALITY: SEATTLE VS. CT.$0
R01 · FY2004 · HS
PROSTATE CANCER SCREENING &MORTALITY: SEATTLE VS. CT.$0
R01 · FY2003 · HS
PROSTATE CANCER SCREENING &MORTALITY: SEATTLE VS. CT.$0
R01 · FY2002 · HS
PROSTATE CANCER SCREENING &MORTALITY: SEATTLE VS. CT.$0
R01 · FY2001 · HS